Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Ventyx's last hope for inflammatory med ends in Crohn's failure
Ventyx’s Crohn’s drug didn't help patients achieve remission in a phase 2 trial, sending the biotech’s shares down 20% pre-market Monday morning.
Annalee Armstrong
Jul 29, 2024 9:45am
BMS axes bispecific months after filing to run phase 3 trial
Jul 26, 2024 8:17am
Sanofi to surf Belharra in $700M biobucks immunology deal
Jun 18, 2024 7:00am
Ex-Kite leader helms Santa Ana’s ship with $168M in hand
Jun 13, 2024 8:00am
AltruBio raises $225M for midphase ulcerative colitis program
May 21, 2024 8:00am
Avalo snaps up AlmataBio for ex-Lilly inflammatory drug
Mar 28, 2024 8:26am
